NEW YORK, March 15, 2021 /PRNewswire/ -- Scopus
BioPharma Inc. (Nasdaq: "SCPS") today announced the
finalization of arrangements for the completion of the
investigational new drug ("IND") package for the company's lead
drug candidate and its submission to the United States Food and
Drug Administration ("FDA"). The IND submission is expected in
Q2 2021.
Scopus is a biopharmaceutical company developing
transformational therapeutics based on groundbreaking scientific
and medical discoveries. The company's lead drug candidate is
a novel, targeted immuno-oncology gene therapy for the treatment of
multiple cancers.
Joshua R. Lamstein, Chairman of
Scopus BioPharma, stated, "We are extremely excited about the
forthcoming submission of the IND for the Phase 1 clinical trial
for our lead drug candidate. We believe investors will
recognize this milestone as an important near-term driver of
shareholder value."
The company's lead drug candidate is highly distinctive,
encompassing both gene therapy and immunotherapy by synthetically
linking siRNA to an oligonucleotide TLR9 agonist, creating the
potential for targeted gene silencing with simultaneous TLR
stimulation and immune activation in the tumor
microenvironment.
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical company developing
transformational therapeutics capitalizing on groundbreaking
scientific and medical discoveries from leading research and
academic institutions. The company's lead drug candidate is a
novel, targeted immuno-oncology gene therapy for the treatment of
multiple cancers. This drug candidate is highly distinctive,
encompassing both gene therapy and immunotherapy by synthetically
linking siRNA to an oligonucleotide TLR9 agonist, creating the
potential for targeted gene silencing with simultaneous TLR
stimulation and immune activation in the tumor
microenvironment. The company is also developing additional
new chemical entities to treat other serious diseases with
significant unmet medical needs, including systemic
sclerosis. Receive updates by following Scopus BioPharma on
Twitter here.
Forward-Looking Statements
This press release may include forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements are subject to risks (including those set forth in the
company's offering circular filed with the U.S. Securities and
Exchange Commission) and uncertainties which could cause actual
results to differ from the forward-looking statements. The company
expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company's
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections.
Contact
Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package-301247064.html
SOURCE Scopus BioPharma Inc.